Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Stock Has Average Target Price of $10.00

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) has been given an average recommendation of “Moderate Buy” by the seven brokerages that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, three have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $10.00.

Several equities research analysts have recently weighed in on AUTL shares. Wall Street Zen upgraded Autolus Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, August 16th. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a report on Monday, August 3rd. Finally, Weiss Ratings raised Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th.

Autolus Therapeutics Stock Performance

Shares of NASDAQ:AUTL opened at $1.91 on Friday. The company has a market capitalization of $508.37 million, a price-to-earnings ratio of -1.80 and a beta of 2.10. Autolus Therapeutics has a 12 month low of $1.18 and a 12 month high of $2.58. The firm’s 50-day moving average is $1.99 and its 200 day moving average is $1.70. The company has a current ratio of 4.89, a quick ratio of 4.40 and a debt-to-equity ratio of 1.04.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.06. Autolus Therapeutics had a negative net margin of 238.66% and a negative return on equity of 178.66%. The company had revenue of $45.69 million for the quarter, compared to analyst estimates of $38.56 million. Research analysts predict that Autolus Therapeutics will post -0.75 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in AUTL. Syncona Portfolio Ltd purchased a new position in Autolus Therapeutics in the 2nd quarter worth about $26,625,152. Alphabet Inc. purchased a new stake in Autolus Therapeutics in the 2nd quarter valued at about $1,117,000. Armistice Capital LLC boosted its position in Autolus Therapeutics by 12.2% in the 4th quarter. Armistice Capital LLC now owns 17,500,000 shares of the company’s stock valued at $34,825,000 after buying an additional 1,900,000 shares during the period. Caitong International Asset Management Co. Ltd grew its stake in Autolus Therapeutics by 55.1% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 44,053 shares of the company’s stock worth $88,000 after acquiring an additional 15,647 shares in the last quarter. Finally, Arizona PSPRS Trust bought a new position in Autolus Therapeutics in the 4th quarter worth about $298,000. 72.83% of the stock is currently owned by institutional investors.

About Autolus Therapeutics

Autolus Therapeutics plc (NASDAQ: AUTL) is a biopharmaceutical company developing and commercializing programmed T-cell therapies for cancer and other serious diseases. The company uses genetic engineering to create CAR T-cell products designed to recognize and eliminate cancer cells while improving control, persistence and safety compared with earlier-generation cell therapies.

Autolus’ lead product, obecabtagene autoleucel, also known as obe-cel and marketed in the United States as AUCATZYL, is a CD19-directed autologous CAR T-cell therapy.